Nature Communications · 2021 · 64 citations · 58 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyCancer TranscriptomicsCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationTumor-infiltrating LymphocytesCd4+ Tumor-infiltrating LymphocytesCd8+ Tumor-infiltrating LymphocytesNon-small Cell Lung Cancer ImmunotherapyProgrammed Cell Death Protein 1 (Pd-1) PathwayTertiary Lymphoid StructuresTumor InteractionsTumor-host Immune InteractionsTumor-immune Crosstalk
Abstract Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we compare tumor-infiltrating lymphocytes between EGFR mutant (EGFR-MT) and wild type (EGFR-WT) tumors through single-cell transcriptomic analysis. We find that B cells, CXCL13-producing follicular helper CD4 + T (T FH )-like cells, and tissue-resident memory CD8 + T (T RM )-like cells decreased in EGFR-MT tumors. The NOTCH-RBPJ regulatory network, which is vital for persistence of T RM state, is perturbed, and the interactions between T FH and B cells through the CXCL13-CXCR5 axis disappear in EGFR-MT tumors. Notably, the proportion of T RM -like cells is predictive for anti-PD-1 response in NSCLC. Our findings suggest that the impairment of T FH -B-T RM cooperation in tertiary lymphoid structure formation, accompanied by the dysregulation of T RM homeostasis and the loss of T FH -B crosstalk, underlies unfavorable anti-PD-1 response in EGFR-MT lung tumors.
58
Comprehensive Integration of Single-Cell Data
Tim Stuart, Andrew Butler, Paul Hoffman et al. · Cell · 2019 · 16.9K citations · Full text
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15